Related Experiment Video
Updated: Oct 13, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Botulinum toxin A in clinical medicine
1National Hospital for Neurology and Neurosurgery, London, England.
Abstract:
The results of the treatment with botulinum toxin A injection of 234 patients with blepharospasm and 73 with hemifacial spasm were reviewed. Visual function improved in the majority of patients with blepharospasm, and the improvement was sustained for up to 40 sets of injections. Mid and lower facial movements were also reduced in a minority of patients. However, a sub-group with pre-tarsal blepharospasm or persistent levator inhibition after treatment had a poor response. An average 75% reduction in abnormal movements was seen in cases of hemifacial spasm. Side effects of the treatment were usually mild and short lived.
Related Concept Videos
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Depolarizing Blockers: Pharmocokinetics
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Tetanus
Botulism

